Mild cognitive impairment (MCI) exhibits considerable heterogeneity, requiring accurate characterization through classification and prognostic models. In clinical research, data-driven models offer valuable insights for classification, stratification, and predicting progression to dementia.
Objective
We implemented computational techniques to characterize MCI patients and develop multistate progression models for Alzheimer's disease (AD).
Methods
Datasets comprising 544 MCI patients from Coimbra University Hospital and 497 from the ADNI, were processed using machine learning techniques, including dimensionality reduction and partition clustering algorithms. For longitudinal measures (n = 351), multistate non-Markov was applied to generate transition probability estimates.
Results
Our analyses gave 4 possible subgroups of MCI patients: 1) increased cognitive reserve, 2) suspected AD pathology, 3) psychological manifestations, and 4) cardiovascular risk factors. Progression within these subgroups showed variations. The likelihood of progressing to AD dementia was estimated over a range of 5 months for those with suspected AD pathology and 66 months for those with psychological manifestations.
Conclusions
Our findings support the significance of computational methods to improve the characterization and prognosis of MCI patients. We suggest that these four MCI subgroups should be considered for clinical monitoring.
PetersenRCSmithGEWaringSC, et al.Mild cognitive impairment: clinical characterization and outcome. Arch Neurol1999; 56: 760.
2.
SantanaIBaldeirasISantiagoB, et al.Underlying biological processes in mild cognitive impairment: amyloidosis versus neurodegeneration. J Alzheimers Dis2018; 64: 647–657.
3.
JackCRJrBennettDABlennowK, et al.NIA-AA Research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement2018; 14: 535–562.
4.
WangXYeTZhouW, et al.Uncovering heterogeneous cognitive trajectories in mild cognitive impairment: a data-driven approach. Alzheimers Res Ther2023; 15: 57.
5.
Tahami MonfaredAAFuSHummelN, et al.Estimating transition probabilities across the Alzheimer's disease continuum using a nationally representative real-world database in the United States. Neurol Ther2023; 12: 1235–1255.
6.
BirkenbihlCSalimiYFröhlichH, et al.Unraveling the heterogeneity in Alzheimer's disease progression across multiple cohorts and the implications for data-driven disease modeling. Alzheimers Dement2022; 18: 251–261.
7.
ZhangLLimCYMaitiT, et al.Analysis of conversion of Alzheimer's disease using a multi-state Markov model. Stat Methods Med Res2019; 28: 2801–2819.
8.
Sanz-BlascoRRuiz-Sánchez de LeónJMÁvila-VillanuevaM, et al.Transition from mild cognitive impairment to normal cognition: determining the predictors of reversion with multi-state Markov models. Alzheimers Dement2022; 18: 1177–1185.
9.
DaduASatoneVKKaurR, et al.Application of Aligned-UMAP to longitudinal biomedical studies. Patterns (NY)2023; 4: 100741.
10.
TijmsBMVromenEMMjaavattenO, et al.Cerebrospinal fluid proteomics in patients with Alzheimer's disease reveals five molecular subtypes with distinct genetic risk profiles. Nat Aging2024; 4: 33–47.
11.
MachuldaMMLundtESAlbertsonSM, et al.Cortical atrophy patterns of incident MCI subtypes in the Mayo Clinic Study of Aging. Alzheimers Dement2020; 16: 1013–1022.
12.
van der HaarDMoustafaAWarrenSL, et al.An Alzheimer's disease category progression sub-grouping analysis using manifold learning on ADNI. Sci Rep2023; 13: 10483.
13.
FaghriFBrunnFDaduA, et al.Identifying and predicting amyotrophic lateral sclerosis clinical subgroups: a population-based machine-learning study. Lancet Digit Health2022; 4: 359–369.
14.
FreitasSSimõesMRAlvesL, et al.Montreal Cognitive Assessment (MoCA): normative study for the Portuguese population. J Clin Exp Neuropsychol2011; 33: 989–996.
15.
GuerreiroM. Contribution of neuropsychology to the study of dementia. Unpublished PhD Thesis. Faculdade de Medicina de Lisboa, Lisboa, Portugal, 1998.
16.
CavacoSGonçalvesAPintoC, et al.Trail making test: regression-based norms for the Portuguese population. Arch Clin Neuropsychol2013; 28: 189–198.
17.
CrumRMAnthonyJCBassettSS, et al.Population-based norms for the Mini-mental state examination by age and educational level. JAMA1993; 269: 2386–2391.
18.
RossettiHCLacritzLHCullumCM, et al.Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample. Neurology2011; 77: 1272–1275.
19.
GrahamDPCullyJASnowAL, et al.The Alzheimer’s disease assessment scale – cognitive subscale: normative data for older adult controls. Alzheimer Dis Assoc Disord2004; 18: 236–240.
20.
GanguliMBiltJVLeeCW, et al.Cognitive test performance predicts change in functional status at the population level: the MYHAT project. J Int Neuropsychol Soc2010; 16: 761–770.
21.
CsuklyGSirályEFodorZ, et al.The differentiation of amnestic type MCI from the non-amnestic types by structural MRI. Front Aging Neurosci2016; 8: 52.
22.
BaldeirasISantanaILeitãoMJ, et al.Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment. Alzheimers Res Ther2018; 10: 33.
23.
SchindlerSEGrayJDGordonBA, et al.Cerebrospinal fluid biomarkers measured by elecsys assays compared to amyloid imaging. Alzheimers Dement2018; 14: 1460–1469.
24.
CostaLMColaçoJCarvalhoAM, et al.Using Markov chains and temporal alignment to identify clinical patterns in dementia. J Biomed Inform2023; 140: 104328.
25.
HairJFBlackWCBabinBJ, et al.Multivariate Data Analysis. 8th ed. London, UK: Cengage Learning,2018.
26.
O’BryantSEWaringSCCullumCM, et al.Staging dementia using clinical dementia rating scale sum of boxes scores: a Texas Alzheimer's research consortium study. Arch Neurol2008; 65: 1091–1095.
27.
BalsisSBengeJFLoweDA, et al.How do scores on the ADAS-Cog, MMSE, and CDR-SOB correspond?Clin Neuropsychol2015; 29: 1002–1009.
28.
GrollemundVLe ChatGSecchi-BuhourMS, et al.Manifold learning for amyotrophic lateral sclerosis functional loss assessment: development and validation of a prognosis model. J Neurol2021; 268: 825–850.
AlbertMSDeKoskySTDicksonD, et al.The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 270–279.
31.
KimKWWooSYKimS, et al.Disease progression modeling of Alzheimer's disease according to education level. Sci Rep2020; 10: 16808.
32.
SternY. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol2012; 11: 1006–1012.
33.
GarbaAEGrossbergGTEnardKR, et al.The influence of cognitive reserve on Alzheimer’s disease progression. Alzheimers Dement2021; 17: 054537.
34.
LinLNiLWangX, et al.Longitudinal cognitive change and duration of Alzheimer's disease stages in relation to cognitive reserve. Neuroscience2022; 504: 47–55.
35.
LopezOLBeckerJTChangY, et al.Amyloid deposition and brain structure as long-term predictors of MCI, dementia, and mortality. Neurology2018; 90: 1920–1928.
36.
XieLDasSRWisseLEM, et al.Baseline structural MRI and plasma biomarkers predict longitudinal structural atrophy and cognitive decline in early Alzheimer's disease. Alzheimers Res Ther2023; 15: 79.
37.
VallettaMVetranoDLXiaX, et al.Multimorbidity patterns and 18-year transitions from normal cognition to dementia and death: A population-based study. J Intern Med2023; 294: 326–335.
MielkeMMRosenbergPBTschanzJ, et al.Vascular factors predict rate of progression in Alzheimer disease. Neurology2007; 69: 1850–1858.
40.
LivingstonGHuntleyJSommerladA, et al.Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet2023; 402: 1132.
41.
KellarDCraftS. Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches. Lancet Neurol2020; 19: 758–766.
42.
AffleckAJSachdevPSStevensJ, et al.Antihypertensive medications ameliorate Alzheimer's disease pathology by slowing its propagation. Alzheimers Dement (NY)2020; 6: 12060.
43.
OlmastroniEMolariGDe BeniN, et al.Statin use and risk of dementia or Alzheimer's disease: a systematic review and meta-analysis of observational studies. Eur J Prev Cardiol2022; 29: 804–814.
44.
Agüera-OrtizLGarcía-RamosRGrandas PérezFJ, et al.Depression in Alzheimer's disease: a Delphi consensus on etiology, risk factors, and clinical management. Front Psychiatry2021; 12: 638–651.
45.
SugarmanMAAloscoMLTripodisY, et al.Neuropsychiatric symptoms and the diagnostic stability of mild cognitive impairment. J Alzheimers Dis2018; 62: 1841–1855.
BallHASwirskiMNewsonM, et al.Differentiating functional cognitive disorder from early neurodegeneration: a clinic-based study. Brain Sci2021; 11: 800.
48.
SainburgTMcInnesLGentnerTQ. Parametric UMAP embeddings for representation and semisupervised learning. Neural Comput2021; 33: 2881–2907.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
